Transformative Gene Therapies for Devastating
Neurological Disorders
Emugen Therapeutics, LLC is a biotechnology company built on a proprietary, innovative, and broadly applicable suite of payload technologies designed to safely harness the power of next-generation IV-deliverable AAV capsids.
About emugen
Inspired by patients and families living with severe genetic diseases, we strive to redefine what is possible in the ever-changing therapeutics landscape.
Launched in 2021 by a renowned group of academic founders and a leadership team from the Broad Institute, Harvard, and MIT. The company is based in the Boston metro area. For more information, follow Emugen on LinkedIn.
Latest News & Updates
Discover how our research is transforming patient care.
Press Release: Apertura Gene Therapy Licenses Blood-Brain Barrier-Penetrant AAV Capsid to Multiple Partners Advancing Central Nervous System Treatments
New York, NY August 13, 2025 – Apertura Gene Therapy, a biotechnology company focused on innovative gene therapy solutions announced several licensing deals with Galibra Neuroscience and Emugen Therapeutics to utilize Apertura’s human transferrin receptor 1 capsid (TfR1 CapX) for their central nervous system (CNS) programs.
our programs
Next-Gen Therapies Driven by Deep Scientific Insight
Our discovery pipeline reflects deep expertise in molecular genetics, genome engineering, and neurobiology. Our team is developing safe, effective gene therapies designed for broad applicability. These advanced tools form the foundation of our discovery platforms—driving us toward a future where best-in-class therapies deliver precise and reliable expression with unmatched safety.
Our science
Next-Gen Therapeutics Engineered to Harness the Power of Next-Gen AAV Capsids
Our best-in-class approach pairs next-generation capsids with cutting-edge payloads, surpassing the limitations of traditional treatments for CNS disorders. With the ability for non-invasive delivery methods, lower viral loads and significantly increased transduction we can create tailored treatments that maximize safe and accurate expression while minimizing side effects.
